Life Sciences

What we do
How can we help
Why KPMG in India
Our insights

Integrated, data-driven and patient-centric ecosystems

India’s life sciences sector is being reshaped by rapid innovation, digital adoption and evolving global operating models. Organisations are increasingly prioritising AI, advanced analytics and automation to improve efficiency, accelerate drug development and enhance patient outcomes. At the same time, the sector continues to respond to regulatory complexity, supply chain pressures and rising expectations on sustainability and patient-centric care, shaping a more resilient and technology-enabled ecosystem.

The industry is also witnessing a fundamental shift in how value is created and delivered. India-based Global Capability Centres (GCCs) are evolving from support functions into core innovation hubs, driving high-value work across R&D, clinical development, regulatory operations and digital health. This transformation is enabling organisations to accelerate time-to-market, improve access and deliver measurable patient impact, while reinforcing India’s role as a strategic hub in the global life sciences value chain.

AI and digital transformation at scale

AI is being embedded across the value chain - from R&D and clinical trials to manufacturing, supply chains and commercial functions - driving efficiency, innovation and new business models
From capability centres to innovation hubs

GCCs in India are shifting to a core-first operating model, leading end-to-end workflows and enabling faster development cycles, improved clinical outcomes and global-scale product innovation
Workforce transformation and talent readiness

Organisations are investing in upskilling, talent development and new operating models, recognising that workforce readiness is critical to unlocking the full value of AI and digital transformation

Regulation, privacy and trust

Increasing regulatory complexity and evolving data privacy frameworks are shaping the need for strong governance, compliance and trust-led operating models across healthcare and life sciences ecosystems
Growth of specialised healthcare segments

Segments such as dermatology are witnessing steady growth, driven by preventive care, OTC expansion, innovation and evolving consumer preferences within healthcare
Shift to intelligent, connected ecosystems

The sector is moving towards integrated, data-driven and patient-centric ecosystems, where digital platforms, AI and data strategies enable better outcomes, operational agility and personalised care delivery

KPMG Global tech report 2026: Life Sciences

A snapshot on technology adoption, investment, and value realisation

How can KPMG in India help?

Our advisory services leverage our deep knowledge in life sciences and our methodologies to manage complex strategic issues such as Mergers and Acquisitions, market entry strategies, new regulatory requirements, people management and growth strategies. Our tax services support pharmaceutical businesses in planning, compliance and reporting of taxes across the spectrum, and our dedicated professionals utilise latest tools and methodologies with their agile perspective to provide constructive inputs.

We are here to enable you to leverage new growth opportunities, enhance your value proposition and help your business to achieve sustained profitability and growth.

Why select KPMG in India?

Life sciences is a global focus sector for us, and KPMG in India has helped leading life sciences companies to successfully reinvent their strategies. Our team is dedicated to assisting businesses of a wide range of sizes from biotechnology start-ups to large multinational pharmaceutical companies. Our services are tailored to the issues that the industry, and your organisation, experience.

Our industry-focused professionals have deep experience across the life sciences sector and continuously strive to keep abreast of industry trends, drivers and issues through knowledge sharing and industry insights programs. We effectively leverage our vast repertoire of skillsets and expertise, our global network and frameworks and methodologies to deliver differentiated offerings and outcomes.

India Union Budget 2026-27: Our Sector Insights

Download KPMG in India point of view 2026 - Life Sciences

KPMG in India point of view 2026 - Pharmaceuticals and Life Sciences

Biopharma shakti proposal, reduction of Basic Customs Duty (BCD) on medicines and push for Ayurveda

Download

Driving growth with Life Sciences trends

Bio Asia 2026
ENRich 2025: Reimagining the Energy Enterprise
Mutual Agreement Procedures

Vijay Chawla
Kartik Ramakrishnan

Nilachal Mishra

Partner and Head, Government & Public Services (G&PS), National Leader - Government and Infrastructure

KPMG in India

mail

India has earned its place as the strategic hub for global transformation. GCCs will shape discovery, influence regulatory pathways, and accelerate product innovation, making India indispensable to the future of Life Sciences.

Kartik Ramakrishnan

Partner - Life Sciences GCC

KPMG in India

mail

Life sciences and healthcare GCCs today are making multiple contributions, from: shaping discovery pipelines, designing medical equipment, owning regulatory initiatives, building digital health platforms, and increasingly co‑owning product and patient outcomes.

And their impact measured in earlier access to therapies. In safer, faster clinical trials. In resilient supply chains. In better patient experiences and outcomes. This is not a future aspiration - it is happening now.
The thriving business ecosystem supporting GCCs plays a proud role in enabling expertise and talent for GCCs in areas like Data Analytics, Taxation, Risk, Regulatory compliance, Technology, Operations support, and even R&D, among others. In addition, startups, Academia, and other platforms enabled by local state governments and private players infuse fresh thinking, talent, and innovation. But what truly sets the GCC ecosystem apart is its collaborative and inclusive nature - GCCs actively encourage newcomers and openly share their experiences. This openness significantly enriches the entire ecosystem in unique and valuable ways.

Vijay Chawla

Partner and Chief Operating Officer – Consulting | Head – Life Sciences

KPMG in India

mail

India has massive potential to lead the medtech revolutions by leveraging its talent, demand, and policy intent. India must scale responsibly, address unmet needs, foster partnerships, and embrace inclusive, open innovation models - especially in rural and underserved areas- while drawing inspiration from global markets like Japan, Singapore, and China. There is need for agile regulatory frameworks, increased investment in infrastructure, and collaborative platforms to drive India-specific innovations that improve accessibility, affordability, and patient outcomes.

Santosh Dalvi

Partner and Deputy Head, Indirect Tax

KPMG in India

mail

Life science companies are subjected to stringent regulation, significant business risks and operate in a very volatile environment. Transfer pricing disputes are very common and severally impact value chain of LS companies.

In this world of uncertainty and prolonged litigation, Mutual Agreement Proceedure (MAP) provides complete and determinative one-time cost-effective mechanism to resolve tax disputes. MAP resolution is binding on revenue authorities and helps in fostering a non-adversarial tax regime. The Action Plan 14 of BEPS project has provided much needed impetus to MAP to emerge as effective and efficient tool for resolution of double taxation related dispute.

India Insights

Our insights is your gateway to thought leadership and in-depth reports. Explore our curated collection of valuable content, where we delve into complex business challenges, share industry trends, and provide actionable insights.